Based on the Ascendis Pharma AS stock forecast from 8 analysts, the average analyst target price for Ascendis Pharma AS is USD 127.25 over the next 12 months. Ascendis Pharma AS’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Ascendis Pharma AS is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Ascendis Pharma AS’s stock price was USD 104.05. Ascendis Pharma AS’s stock price has changed by +12.80% over the past week, +9.93% over the past month and -17.02% over the last year.
No recent analyst target price found for Ascendis Pharma AS
No recent average analyst rating found for Ascendis Pharma AS
Company Overview Ascendis Pharma AS
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900 Read Less
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and t...Read More
Frequently Asked Questions About Ascendis Pharma AS (ASND) Stock
Based on ratings from 8 analysts Ascendis Pharma AS's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on ASND's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for ASND is USD 127.25 over the next 12 months. The maximum analyst target price is USD 192 while the minimum anlayst target price is USD 89.
ASND stock's Price/Earning ratio is 1.19.
Our analysis grades ASND stock's Price / Earning ratio at D+. This means that ASND stock's Price/Earning ratio is above 32% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ASND may be fairly valued for its sector
The last closing price of ASND's stock was USD 104.05.
The most recent market capitalization for ASND is USD 5.88B.
Based on targets from 8 analysts, the average taret price for ASND is projected at USD 127.25 over the next 12 months.
This means that ASND's stock price may go up by +22.30% over the next 12 months.
We can't find any ETFs which contains Ascendis Pharma AS's stock.
As per our most recent records Ascendis Pharma AS has 797 Employees.
Ascendis Pharma AS's registered address is 200 Bay Street, Toronto, ON, Canada, M5J 2J2.
You can get more information about it from Ascendis Pharma AS's website at https://www.ascendantresources.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ASND !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
